Skip to search formSkip to main contentSkip to account menu

BPR0L075

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Paclitaxel plays a major role in the treatment of ovarian cancer; however, resistance to paclitaxel is frequently observed. Thus… 
2012
2012
BPR0L075, 6-methoxy-3-(3′,4′,5′-trimethoxy-benzoyl)-1H-indole, is a tubulin-binding agent that inhibits tubulin polymerization by… 
Highly Cited
2011
Highly Cited
2011
Utilizing scaffold-hopping drug-design strategy, we sought to identify a backup drug candidate for BPR0L075 (1), an indole-based… 
Highly Cited
2010
Highly Cited
2010
Background Anti-mitotic compounds (microtubule de-stabilizers) such as vincristine and vinblastine have been shown clinically… 
2010
2010
BACKGROUND Antimitotic tubulin-binding BPR0L075 is structurally analogous to the vascular-disrupting combretastatin A-4… 
Highly Cited
2009
Highly Cited
2009
BPR0L075 (2) is a potential anticancer drug candidate designed from Combretastatin A-4 (1) based on the bioisosterism principle… 
2009
2009
Several small weight indole derivatives (D-64131, D-24851, BPR0L075, BLF 61-3, and ATI derivatives) are potent tubulin… 
2007
2007
6-Methoxy-3-(3′,4′,5′-trimethoxy-benzoyl)-1H-indole (BPR0L075) is a novel synthetic indole compound with microtubule binding… 
2006
2006
The concise synthesis and structure–activity relationship (SAR) studies of 3‐aroylindoles were carried out in an effort to… 
Highly Cited
2004
Highly Cited
2004
BPR0L075 is a novel synthetic compound discovered through research to identify new microtubule inhibitors. BPR0L075 inhibits…